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Altered lipid metabolism underlies several major human diseases, including obesity and type 2 diabetes. 
However, lipid metabolism pathophysiology remains poorly understood at the molecular level. Insulin is the 
primary stimulator of hepatic lipogenesis through activation of the SREBP-1c transcription factor. Here we 
identified cyclin-dependent kinase 8 (CDK8) and its regulatory partner cyclin C (CycC) as negative regulators 
of the lipogenic pathway in Drosophila, mammalian hepatocytes, and mouse liver. The inhibitory effect of 
CDK8 and CycC on de novo lipogenesis was mediated through CDK8 phosphorylation of nuclear SREBP-1c 
at a conserved threonine residue. Phosphorylation by CDK8 enhanced SREBP-1c ubiquitination and protein 
degradation. Importantly, consistent with the physiologic regulation of lipid biosynthesis, CDK8 and CycC 
proteins were rapidly downregulated by feeding and insulin, resulting in decreased SREBP-1c phosphoryla-
tion. Moreover, overexpression of CycC efficiently suppressed insulin and feeding–induced lipogenic gene 
expression. Taken together, these results demonstrate that CDK8 and CycC function as evolutionarily con-
served components of the insulin signaling pathway in regulating lipid homeostasis.
Introduction
Dysregulation of lipid metabolism is closely associated with major 
human diseases such as obesity, type 2 diabetes, and cardiovascular 
disease (1–4). However, the physiologic and pathophysiologic regu-
lation of lipid metabolism is a highly complex and integrative pro-
cess that remains poorly understood at the molecular level. Among 
the known lipogenic regulators, the SREBP transcription factors 
are pivotal activators of key enzymes responsible for hepatic bio-
synthesis of fatty acids and cholesterol (5–8) and play an important 
role in the development of fatty liver and dyslipidemia (9).
The three mammalian SREBP transcription factors, SREBP-1a, 
-1c, and -2, are synthesized as inactive precursors that are tethered 
to the ER membrane (10). Reduction of intracellular sterols results 
in the transportation of SREBP-2 to the Golgi, where it undergoes 
proteolytic maturation. Then, the N-terminal fragment of SREBP-2 
translocates into the nucleus and activates transcription of tar-
get genes (11). Similarly, the two SREBP-1 isoforms, SREBP-1a 
and -1c, are also processed in the Golgi to generate the mature 
SREBP-1 protein (12, 13). Unlike SREBP-2, SREBP-1c is primarily 
activated by insulin (14). Both SREBP-1a and SREBP-1c proteins 
are produced by the same gene, SREBF1, by two distinct promot-
ers and alternative splicing (15). Their amino acid sequences differ 
only at the very N-terminal end. The unique region of SREBP-1a is 
part of its transactivation domain (16). SREBP-1a and SREBP-1c 
have different expression profiles: SREBP-1a is highly expressed 
in proliferating cells, such as cancer cells, while SREBP-1c is the 
predominant form in normal cells, particularly hepatocytes (17).
CDK8 and its regulatory partner CycC have been reported as 
being subunits of the Mediator complexes in mammalian cells 
(18, 19). The mammalian Mediators are large protein complexes 
containing up to 30 distinct subunits, depending on starting 
materials and biochemical purification protocols, and play a 
critical role in bridging the signals from transcription factors to 
the basal transcription apparatus (20–22). Biochemical purifica-
tions have identified at least two groups of Mediator complex-
es, the small Mediator and the large Mediator, with the latter 
containing an extra submodule of CDK8, CycC, MED12, and 
MED13 (19). In chromatin-based in vitro transcription assays, 
the small Mediator can activate gene transcription, while the 
large Mediator is inactive (19). Interestingly, recent studies have 
established a role of CDK8-CycC in tumorigenesis (20). How-
ever, the in vivo functions and regulation of CDK8 and CycC are 
still poorly understood.
In this study, we identify CDK8 and CycC as key repressors for 
lipogenic gene expression, de novo lipogenesis, and lipid accu-
mulation in Drosophila and mammals. This function of CDK8-
CycC occurs through site-specific phosphorylation on nuclear 
SREBP-1c protein, resulting in rapid degradation of this central 
regulator of lipid metabolism. Since CDK8 and CycC are reduced 
upon feeding or by insulin, concomitant with increased levels of 
nuclear SREBP-1c protein, the CDK8-CycC complex appears to 
function downstream of the insulin signaling as a key regulator 
of de novo lipogenesis.
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Results
CDK8 and CycC regulate lipid levels and lipogenic gene expression in Dro-
sophila. CDK8 and CycC are highly conserved in eukaryotes; thus, 
we first used Drosophila as a model organism to study function 
and regulation of CDK8 and CycC in vivo. Compared with wild-
type (Figure 1A), Cdk8-null (Figure 1B) and CycC-null (Figure 1C) 
larvae are less transparent, suggesting that the mutant larvae pos-
sess more fat tissue. Intrigued by this observation, we stained fat 
body of larvae, which is the predominant tissue for regulating lipid 
homeostasis in Drosophila, with oil red O for neutral lipids (Supple-
mental Figure 1; supplemental material available online with this 
article; doi:10.1172/JCI61462DS1) and extracted the dye with iso-
propanol. As shown in Figure 1D, we detected significantly more 
oil red O staining in Cdk8- and CycC-null larvae. Quantitative mea-
surements of triglycerides in Cdk8- and CycC-null larvae further 
confirmed the significant increase in neutral lipids as compared 
with control (Figure 1E). To avoid potential nonspecific effects of 
Cdk8 or CycC mutations on lipid metabolism during development, 
we generated transgenic RNAi lines that allow tissue-specific 
knockdown of CDK8 or CycC. Similarly, we observed a significant 
increase in lipid levels in larvae with either CDK8 or CycC knock-
down by RNAi whose expression is driven by fat body–specific 
FB-Gal4 (Figure 1F) or Adh-Gal4 (data not shown). Taken together, 
these results suggest that CDK8 and CycC are required for inhibi-
tion of lipid accumulation in Drosophila larvae.
To investigate the underlying mechanisms of increased lipid 
levels in Cdk8 and CycC mutants in an unbiased fashion, we 
examined the global gene expression profiles in homozygous 
null mutant larvae of Cdk8 and CycC at the late third instar stage 
by cDNA microarray analysis. Both Cdk8K185 and CycCY5 are null 
alleles, and homozygous mutants are lethal as pupae (23). Com-
pared with the control, a number of genes in Cdk8-null mutants 
were significantly altered, with a cutoff at 1.5-fold and a false dis-
covery rate of less than 0.05 (Figure 2A). More than 80% of these 
genes (662 of upregulated and 807 of downregulated genes) were 
also altered in CycC-null mutants in the same fashion (Figure 2A). 
The high percentage of overlapping genes supports a model 
whereby CycC is required for activation of CDK8 (20, 23–26). In 
addition, the known dE2F1 target genes were also found to be 
upregulated in this microarray analysis (data not shown), con-
firming our previous finding that CDK8 inhibits E2F1-depen-
dent transcription (27).
Consistent with our observation of the phenotypic changes in 
Cdk8- or CycC-null larvae, many genes involved in lipid metabo-
lism were significantly upregulated in those mutants (Supplemen-
tal Table 1). These genes include fatty acid synthase (dFAS), acetyl-
CoA carboxylase (dACC), and acetyl-CoA synthetase (dACS), which 
are important enzymes for fatty acid biosynthesis. As confirmed 
by reverse transcription and quantitative PCR (qRT-PCR), we 
observed a significant increase in transcripts of dACC, dACS, dFAS, 
and other genes in Cdk8- and CycC-null mutants compared with 
the control (Figure 2, B and C), suggesting that CDK8 and CycC 
are required for inhibition of the transcription of these genes.
Interestingly, the mammalian homologs of several genes in Sup-
plemental Table 1 are known transcriptional targets of SREBP tran-
scription factors (28, 29), which are the master regulators of lipid 
homeostasis in diverse organisms (10, 30, 31). Consistent with the 
lipogenic function of SREBP, knocking down Drosophila SREBP 
(dSREBP) in fat body significantly reduced lipid levels (Figure 1F). 
Thus, we postulate that CDK8 and CycC may regulate the expres-
Figure 1
Role of CDK8 and CycC in lipid accumulation in fat bodies of Drosophila larvae. Representative light micrographic images for larvae (scale bars: 
1.0 mm) of (A) wild-type (w1118), (B) Cdk8-null (k185), and (C) CycC-null (y5) Drosophila. (D) Quantitative measurement of oil red O staining in 
Drosophila larvae of the indicated genotypes. (E) Triglyceride levels in Drosophila larvae of the indicated genotypes. (F) Quantitative measure-
ment of oil red O staining in Drosophila larvae with fat body–specific expression of the indicated RNAi; the background control was FB-Gal4. Data 
represent mean ± SD of 15 larvae per genotypes for oil red O staining or 3 random pools of the same genotype for triglyceride measurement. 
*P < 0.01, #P < 0.001 versus control. Data are representative of independent experiments repeated at least 3 times.
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sion of lipogenic genes through repression of SREBP-mediated 
transcription. To test this hypothesis, we knocked down both 
CDK8 (or CycC) and dSREBP in fat body and observed a signifi-
cant reduction in neutral lipid levels compared with knockdown 
of CDK8 (or CycC) alone (Figure 1F). These results suggest that 
the effect of CDK8 or CycC knockdown on lipid accumulation is 
likely dependent on SREBP. However, the mRNA levels of dSREBP 
and dSCAP were not significantly changed in Cdk8- and CycC-null 
mutants (Supplemental Table 1), suggesting that the effect of 
CDK8 and CycC on SREBP target gene expression in Drosophila 
was less likely mediated through regulation of the transcription 
or maturation of dSREBP itself.
CDK8 and CycC repress the lipogenic program in mammalian 
hepatocytes. To determine whether CDK8 regulation of lipid accu-
mulation and lipogenic gene expression is conserved in mamma-
lian cells, we knocked down CDK8 or CycC in primary culture of 
rat hepatocytes using lentiviral shRNA (Figure 3A). Knockdown 
of CDK8 or CycC resulted in a significant increase in triglycerides 
(Figure 3B), suggesting that as in Drosophila larvae, CDK8 and 
CycC are required for inhibition of intracellular triglyceride accu-
mulation in primary rat hepatocytes. To test whether CDK8 and 
CycC also regulate the transcription of FAS, we knocked down 
CDK8 or CycC in HepG2 cells that were cotransfected with the 
FAS luciferase reporter (32). As shown in Figure 3C, CDK8 or 
CycC knockdown with two independent shRNAs, as we used 
previously (27), resulted in significant elevation of FAS promoter 
activity, indicating that CDK8 and CycC negatively regulate the 
FAS promoter. Consistent with the concept that a functional inter-
action of CDK8 and CycC is necessary for stability of the CDK8-
CycC complex, CDK8 knockdown in mammalian cells resulted 
in a concomitant reduction in CycC, while CycC knockdown 
caused a parallel reduction in CDK8 in cultured cells (Figure 3, 
A and C). In addition, CDK8 or CycC knockdown (Figure 3D) 
significantly increased the mRNA levels of endogenous SREBP 
target genes, such as FAS, ACC, ATP-citrate lyase (ACLY), and stea-
royl CoA desaturase (SCD1), in three hepatocyte lines: primary rat 
hepatocytes (Figure 3E), FAO cells (data not shown), and HepG2 
cells (Supplemental Figure 2A). The effect of CDK8 or CycC 
knockdown was compromised when SREBP-1 was co-depleted in 
those cells by shRNA (Figure 3E and Supplemental Figure 2A), 
similar to what we observed in Drosophila (Figure 1F). These results 
support the hypothesis that regulation of lipogenic gene expres-
sion by CDK8 is dependent on SREBP-1. Furthermore, CDK8 
knockdown significantly stimulated the activity of a promoter 
with wild-type SREBP-1 binding sites (SRE) in HEK293 cells, but 
had no effects when the SRE site was inactivated by point muta-
tions (Supplemental Figure 2B), further suggesting that CDK8 
represses SREBP-1–dependent gene expression. Consistent with 
the mRNA level and promoter activity of FAS gene, FAS protein 
levels in primary rat hepatocytes (data not shown) and HepG2 
cells (Figure 4A) were also significantly elevated when CDK8 or 
CycC was knocked down. Taken together, our data suggest that 
CDK8 and CycC regulate SREBP-dependent gene expression in 
mammalian hepatocytes.
Cdk8 and CycC are involved in regulating nuclear SREBP-1 protein 
stability. To elucidate the molecular mechanisms of CDK8 inhi-
bition of SREBP-1–mediated lipogenic gene expression, we first 
asked whether CDK8 affects the abundance of nuclear SREBP-1 in 
mammalian cells. CDK8 or CycC knockdown resulted in a signifi-
cant increase in endogenous nuclear SREBP-1 protein in primary 
rat hepatocytes (Figure 3A) and HepG2 cells (Figure 4A), with no 
significant change in the protein levels of the SREBP-1 precursor 
(Figure 3A and Figure 4A), suggesting that CDK8 regulates the 
abundance of the nuclear form of this transcription factor.
The nuclear/active form of SREBP-1 is processed from its pre-
cursor initially located in ER membrane (13). Since CDK8 is pre-
dominantly a nuclear protein (33), it is less likely that CDK8 can 
directly regulate the proteolytic maturation process of SREBP-1 in 
ER or Golgi apparatus, which is also supported by our data in pri-
mary rat hepatocytes (Figure 3A and Figure 4A). Thus, to further 
analyze the effect of CDK8 on nuclear SREBP-1 protein levels, we 
initially overexpressed a Flag-tagged nuclear form of SREBP-1a 
in HEK293 cells by transient transfection. As a control, an HA-
tagged fusion protein of the Gal4 DNA-binding domain and Myb 
transactivation domain, which is neither physically nor function-
ally associated with CDK8 or CycC (32, 34), was coexpressed. 
As shown in Figure 4B, depletion of CDK8 by shRNAs caused 
accumulation of the nuclear form of SREBP-1a. Similar results 
were obtained when CycC was knocked down (data not shown). 
The increased accumulation of the nuclear form of SREBP-1a 
in HEK293 cells caused by CDK8 or CycC knockdown was due 
to decreased protein degradation as assayed by Western blots in 
the presence of cycloheximide, an inhibitor of protein synthesis 
(Figure 4, C and D). These data support a model in which CDK8-
CycC regulates SREBP target gene expression at least in part by 
controlling the stability of nuclear SREBP-1 proteins.
Figure 2
Role of CDK8 and CycC in gene expression in Drosophila larvae. (A) Number of genes whose expression was significantly changed in Cdk8-null 
and CycC-null Drosophila larvae identified by cDNA microarray analysis. (B and C) The mRNA levels of representative lipogenic genes determined 
by qRT-PCR using rp49 as the invariant control. Data represent mean ± SD of 3 random pools of the same genotype. *P < 0.01 versus control.
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CDK8 directly phosphorylates SREBP-1. Since ubiquitination is 
required for SREBP-1 degradation (35), we determined whether 
CDK8 and CycC affected SREBP-1a ubiquitination by coexpressing 
HA-tagged ubiquitin with Flag-tagged nuclear SREBP-1a in HEK293 
cells. As shown in Figure 4E, the amount of ubiquitinated SREBP-1a 
was significantly decreased in cells with CDK8 or CycC knockdown 
by shRNAs. Moreover, CDK8 knockdown also decreased the ubiqui-
tination levels of endogenous SREBP-1 (Figure 4F).
Phosphorylation of SREBPs has been shown to facilitate their 
binding to the E3 ligase SCFFbw7b, thus controlling their ubiquitina-
tion and subsequent degradation (35). Because CDK8 can directly 
phosphorylate several proteins in multicellular organisms (27, 
36–38), we tested the possibility that CDK8 alters SREBP-1a stabil-
ity through direct phosphorylation. Since the consensus sequence 
motifs for cyclin-dependent kinases are generally threonine (T) or 
serine (S) followed by a proline residue (TP or SP), we used a commer-
cially available antibody that specifically recognizes phosphorylated 
TP (p-TP) as well as an antibody that can recognize phosphorylated 
serine (p-S) to detect the phosphorylation status of SREBP-1a. 
By Western blot analysis of immunoprecipitated SREBP-1a, 
we found that CDK8 or CycC knockdown in HEK293 cells dra-
matically decreased the phosphorylation levels of SREBP-1a 
at TP motifs, but had no significant effects on phosphorylation 
at serine residues (Figure 5A), suggesting that CDK8 or CycC only 
regulates threonine phosphorylation of SREBP-1a. To determine 
whether CDK8 can also directly phosphorylate SREBP-1c, we per-
formed in vitro kinase assays in which endogenous CDK8 proteins 
were immunopurified from nuclear extracts of HEK293 cells, and 
recombinant GST–SREBP-1c (amino acids 1–426) protein was used 
as the potential substrate. As shown in Figure 5B, native CDK8, 
but not heat-inactivated CDK8, could phosphorylate SREBP-1c in 
vitro at TP motifs, but not serine residues. To eliminate the possi-
bility of contamination by other cellular kinases, we immunopuri-
fied Flag-tagged CDK8 proteins from nuclear extracts of HEK293 
cells that were transfected with either wild-type or a kinase-dead 
mutant of CDK8. As shown in Figure 5C, wild-type CDK8, but 
not the kinase-defective mutant, could phosphorylate SREBP-1c 
in vitro, confirming that SREBP-1c is a direct substrate of CDK8. 
Moreover, only CDK8, but not the closely related nuclear CDK7 
and CDK9, was able to phosphorylate SREBP-1c at TP motifs, and 
none of them was able to phosphorylate SREBP-1c on serine resi-
dues in vitro (data not shown). Consistent with a previous report 
(39), all of these kinases could phosphorylate the CTD tail of RNA 
polymerase II (RNAPII) in vitro (data not shown).
There are 5 TP motifs within the nuclear form of human SREBP-1c 
(Figure 5D). To determine which TP motifs are targeted by CDK8, 
we performed in vitro kinase assays with several truncated forms 
of SREBP-1c (Figure 5D). Only the fragments containing the T402 
Figure 3
CDK8 and CycC regulate SREBP-1–dependent lipogenic gene expression in mammalian hepatocytes. (A and D) Immunoblots for the indicated 
proteins in primary rat hepatocytes after treatment with lentivirus expressing the indicated shRNA. Pre-SREBP-1, precursor SREBP-1; nSREBP-1, 
nuclear SREBP-1. (B) Effects of CDK8 or CycC knockdown by lentiviral shRNA on triglyceride levels in isolated primary rat hepatocytes. (C) 
Effect of CDK8 or CycC knockdown by shRNA on FAS promoter–driven firefly luciferase mRNA levels in HepG2 cells as measured by qRT-PCR. 
The β-actin–driven Renilla luciferase served as control. (E) mRNA levels of endogenous SREBP target genes in primary rat hepatocytes were 
detected by qRT-PCR after treatments of the indicated lentiviral shRNA. Cyclophilin B served as the invariant control, and the mRNA levels of 
each gene were normalized to those in the non-silencing (NS) shRNA–treated sample. Data represent mean ± SD of 3 independent treatments. 
*P < 0.01 versus control.
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residue (Figure 5E), which is located in a highly conserved region 
(Figure 5F), can be phosphorylated by CDK8 in vitro, suggesting 
that the T402 residue of human SREBP-1c is likely the direct target 
site of CDK8. To determine whether CDK8 affects phosphoryla-
tion of SREBP-1c T402 in cultured cells, we mutated this residue to 
alanine (T402A mutation) and transfected the Flag-tagged mutant 
as well as wild-type SREBP-1c into HEK293 cells. Consistent with 
our in vitro results, T402A mutant SREBP-1c was more stable than 
the wild type SREBP-1c in HEK293 cells (Figure 5G). Similar to our 
data on SREBP-1a (Figure 4B), CDK8 knockdown also induced 
accumulation of nuclear SREBP-1c, but the protein levels of the 
T402A mutant, unlike wild-type SREBP-1c, were not affected by 
CDK8 knockdown (Figure 5G). In addition, the phosphorylation 
levels of TP motifs in T402A mutant SREBP-1c were dramatically 
decreased, albeit not completely lost (Figure 5G), and CDK8 knock-
down no longer had significant effects on TP phosphorylation of 
T402A mutant SREBP-1c (Figure 5G). These results strongly sup-
port the hypothesis that the conserved T402 is the primary target 
of TP motif phosphorylation by CDK8, but the non-conserved TP 
motifs can have minor phosphorylation by other unknown kinases 
in HEK293 cells. Functionally, CDK8 knockdown can stimulate 
wild-type SREBP-1c– but not T402A SREBP-1c–mediated activa-
tion of the FAS promoter (Supplemental Figure 3). Our results are 
consistent with a previous report showing that phosphorylation of 
the analogous T426 residue of SREBP-1a is critical for its binding to 
the E3 ligase SCFFbw7b, which is also involved in regulating nuclear 
SREBP-1a protein stability (35). Thus, our data directly demon-
strate that CDK8 functions as a novel kinase of SREBP-1c.
Knockdown of CDK8 causes lipid accumulation in mice. The regulation of 
lipogenesis in cultured hepatocytes, particularly cancer cell lines, may 
not necessarily reflect the physiologic regulation in vivo. However, 
conventional CDK8 knockouts are embryonic lethal (40), and condi-
tional CDK8-knockout mice are not yet available. Thus, to avoid the 
developmental defects of Cdk8 gene ablation, we transiently knocked 
down CDK8 in mouse livers by tail vein injection of adenovirus 
expressing specific shRNA against CDK8 (Figure 6A). Similar to 
our data from cell culture, CDK8 knockdown in mouse liver caused 
a significant increase in protein levels of FAS (Figure 6, A and B) 
and the nuclear, but not precursor, form of SREBP-1c (Figure 6A). 
In addition, we found that the SREBP-1c target genes FAS, ACS, and 
SCD1 were all significantly upregulated in CDK8-knockdown mouse 
livers compared with non-silencing shRNA–adenovirus infected 
samples (Figure 6C). In addition, CDK8 knockdown in liver had no 
significant effect on Srebp1 or Srebp2 mRNA expression (Supplemen-
tal Figure 4A) or L-pyruvate kinase (Figure 6C). The latter is not regu-
lated by SREBP-1c (41), but it is a target of another important lipo-
genic transcription factor, carbohydrate regulatory element binding 
protein (ChREBP) (42, 43). These results suggest an inhibitory role 
of CDK8 on lipogenic gene expression in vivo through the regulation 
of nuclear SREBP-1c. Consistent with the increased lipogenic gene 
expression, the hepatic de novo synthesis rate of palmitate was signif-
icantly elevated by injection of adenoviral CDK8 shRNA (Figure 6D). 
As a result, hepatic triglyceride levels were also significantly increased, 
by about 2-fold (Figure 6E), with accumulation of neutral lipids in 
mouse livers as detected by oil red O staining (Figure 6, G versus F), 
revealing a phenotype of early-stage fatty liver in CDK8-knockdown 
Figure 4
CDK8 and CycC regulate SREBP-1 protein stability. (A) Effects of CDK8 and CycC knockdown on protein levels of FAS and SREBP-1 in HepG2 
cells. (B) Effects of CDK8 knockdown on protein levels of overexpressed Flag-tagged nuclear SREBP-1a in HEK293 cells. The HA-tagged fusion 
protein of the transactivation domain of Myb and Gal4 DNA-binding domain served as control. (C) Representative immunoblots and (D) relative 
levels of overexpressed Flag-tagged nuclear SREBP-1a in HEK293 cells in the presence of cycloheximide (CHX) for the indicated amount of 
time after CDK8 or CycC knockdown. (E) Effects of CDK8 or CycC knockdown on SREBP-1a ubiquitination. Flag-tagged nuclear SREBP-1a 
was cotransfected with HA-tagged ubiquitin (HA-Ub) and the indicated shRNA plasmids in HEK293 cells. After approximately 40 hours of cul-
ture followed by 3 hours of treatment with 0.1 mM MG132, cell lysates were prepared. The amount of SREBP-1a proteins was normalized after 
immunoprecipitation from cell lysate, and the presence of HA-ubiquitin modifications was detected by immunoblotting using anti-HA antibody. (F) 
Endogenous nuclear SREBP-1 proteins were immunoprecipitated from HEK293 cells after lentiviral CDK8 (or NS) shRNA treatment for 48 hours, 
followed by 3 hours of treatment with 0.1 mM MG132. The presence of ubiquitinated proteins was detected by anti-ubiquitin antibody.
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mice. Strikingly, CDK8 knockdown also resulted in a concomitant 
increase in plasma triglycerides (~5-fold) (Supplemental Figure 4B), 
but no change in circulating insulin (Supplemental Figure 4C), free 
fatty acids (Supplemental Figure 4D), or glycerol (Supplemental Fig-
ure 4E). These results suggest that hypertriglyceridemia in CDK8-
knockdown mice was not due to changes in adipocyte lipolysis. 
Thus, our data from mouse livers support the hypothesis that CDK8 
plays a critical role in regulating de novo lipogenesis and triglyceride 
levels in mammals.
Regulation of CDK8 and CycC by nutrients. Since food intake gener-
ally stimulates lipogenesis in liver, we examined the protein levels 
of nuclear SREBP-1c, CycC, and CDK8 in mouse liver in fasted and 
re-fed states. Consistent with a previous report (44), compared with 
mice fasted for 12 hours, those re-fed for 5 hours had higher levels 
of nuclear SREBP-1c (Figure 7A). Interestingly, re-feeding resulted 
in a significant decrease in nuclear levels of both CDK8 and CycC 
proteins in mouse liver (Figure 7A), suggesting that CDK8 and CycC 
are regulated during fasting and re-feeding. Although a complicated 
set of changes takes place from the fasting to fed state, insulin is 
a primary lipogenic factor upon food intake, and it stimulates de 
novo lipogenesis primarily by stimulating SREBP-1c at the levels of 
transcription, processing, and nuclear protein stability (14). Thus, 
we tested whether insulin has any effects on CDK8 or CycC levels 
in hepatocytes. As shown in Figure 7B, insulin treatment caused 
downregulation of both CDK8 and CycC proteins in primary rat 
hepatocytes. We also observed a similar effect of insulin in FAO and 
HEK293 cells (data not shown). Moreover, insulin treatment also 
markedly decreased the phosphorylation of nuclear form of endog-
enous SREBP-1c at TP sites in primary rat hepatocytes (Figure 7C).
After establishing the role of feeding and insulin in downregu-
lating CDK8-CycC, we examined whether overexpression of CycC 
and/or CDK8 can antagonize the effects of insulin. As expected, 
insulin treatment caused accumulation of overexpressed Flag-
tagged nuclear form of SREBP-1a in HEK293 cells (Figure 7D, lane 
3 vs. lane 1). Overexpression of CycC decreased the protein levels of 
SREBP-1a in the absence of insulin and blocked insulin-induced 
Figure 5
Direct phosphorylation of SREBP-1 by CDK8. (A) Effects of CDK8 or CycC knockdown on SREBP-1a phosphorylation in HEK293 cells. Flag-
tagged nuclear SREBP-1a was cotransfected with the indicated shRNA plasmids in HEK293 cells. Cell lysates were prepared after approximately 
40 hours of culture. SREBP-1a proteins were immunoprecipitated from cell lysate and normalized. The presence of p-TP motifs and p-S residues 
was detected by immunoblotting using specific antibodies. (B and C) In vitro kinase assays were performed to determine kinase activity toward 
GST-SREBP-1c (aa 1–426) at TP motifs using the following immunopurified kinases from nuclear extract: (B) endogenous CDK8; and (C) Flag-
tagged wild-type or kinase-dead (KD) mutant CDK8 by transient transfection. (D) SREBP-1c fragments used for mapping CDK8 target sites. 
(E) Identification of CDK8 target site by in vitro kinase assays. (F) Conservation of CDK8 phosphorylation site in SREBPs. (G) Effects of CDK8 
knockdown on Flag-tagged WT or T402A mutant SREBP-1c protein levels and phosphorylation at TP motifs in HEK293 cells.
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accumulation of SREBP-1a (Figure 7D). Furthermore, overexpres-
sion of CycC completely inhibited insulin-induced activation of 
the FAS promoter (Figure 7E). However, overexpression of wild-
type CDK8 had little effect on the FAS promoter (data not shown). 
This is probably because increasing CDK8 alone is not sufficient 
for CDK8 kinase activity, substrate recognition, and/or localization 
in the absence of CycC. Finally, CycC overexpression in fat body of 
Drosophila larvae also inhibited re-feeding–induced upregulation of 
expression of lipogenic genes, such as dFAS (Figure 7F), and triglyc-
eride accumulation (data not shown). Together, our data strongly 
support a functional role of CDK8-CycC in feeding/insulin-
induced activation of nuclear SREBP-1c and de novo lipogenesis.
Discussion
In contrast to the sterol regulation of SREBP-2, insulin functions 
as the major activator of SREBP1C gene expression and inducer of 
SREBP-1c precursor processing to the mature nuclear form (5, 45–47). 
Numerous studies have established a key role of nuclear SREBP-1c 
on lipogenic gene expression and de novo lipogenesis (6, 16, 28, 44, 
48). In this regard, SREBP-1c levels are elevated in mice and humans 
under a variety of pathophysiologic states, including obesity, insulin 
resistance associated with hyperinsulinemia, high carbohydrate diet, 
excessive alcohol consumption, and non-alcoholic fatty liver disease 
(NAFLD) — in the case of the latter being directly shown to increase 
the proportion of liver VLDL triglyceride production by de novo 
lipogenesis from 2%–5% to 20%–30% (41, 49–52). In those disease 
states, it is generally thought that the increased de novo lipogenesis 
results from high levels of insulin driving SREBP-1c transcription 
and precursor processing through PI3K- and mTORC1-dependent 
pathways, despite the marked insulin resistance to gluconeogen-
esis (14, 53, 54). However, these studies have only focused on the 
mechanisms of transcriptional activation of SREBP-1c expression 
and have not considered changes in the transcriptional activity or 
protein stability of nuclear SREBP-1c protein.
In this study, we identified a highly conserved role for CDK8 
in the control of fatty acid and triglyceride metabolism. In Dro-
sophila larvae, loss of CDK8 or CycC increased SREBP-dependent 
neutral lipid accumulation in fat body and lipogenic gene expres-
sion. Similarly, RNAi knockdown in hepatocytes in vitro or mouse 
liver in vivo also increased triglyceride levels, along with increasing 
SREBP target gene expression and de novo lipogenesis. Surpris-
ingly, CycC and CDK8 levels were negatively regulated by food 
intake in mouse liver and by insulin in cultured cells. Thus, we pro-
pose a model whereby insulin stimulates de novo lipogenesis by 
downregulating the CDK8-CycC complex, which normally inhib-
its de novo lipogenesis through promoting nuclear SREBP-1c 
degradation. This new mechanism of insulin-induced lipogenesis 
is in addition to the well-documented function of insulin in stimu-
lating SREBP-1c at the transcriptional level. Consistent with our 
model, overexpression of CycC blocks insulin-induced stabiliza-
tion of nuclear SREBP-1 and lipogenic gene expression in vitro 
and in vivo. These observations establish an important and physi-
ological role of CDK8-CycC in regulating fatty acid biosynthesis.
CDK8 and CycC are best known for their functions as the sub-
units of the Mediator complex, which serves as a transcription cofac-
tor complex (26). Along with MED12 and MED13, they form the 
Figure 6
CDK8 knockdown in mouse liver increases de novo lipogenesis. (A) Representative immunoblots for the indicated proteins after tail vein injec-
tion of adenoviruses expressing shRNA in mouse liver. (B) Relative amount of FAS proteins after the indicted treatments. (C–G) Effects of CDK8 
knockdown by adenoviral shRNA in mouse livers in vivo on lipogenic gene expression as detected by qRT-PCR (C), synthesis rate of hepatic 
palmitate as analyzed by GC-MS (D), hepatic triglyceride levels (E), and hepatic lipid accumulation as visualized by oil red O staining (G; con-
trol is shown in F; scale bar: 0.01 mm). L-PK, L-pyruvate kinase. Data represent mean ± SD (n = 6 mice for each treatment). For CDK8 shRNA, 
§P < 0.05 and #P < 0.001 versus control.
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CDK8 submodule of the Mediator complex. However, unlike that 
of CDK8 and CycC, fat body–specific knockdown of MED12 and 
MED13 did not cause statistically significant changes in lipid levels 
in Drosophila larvae, although there was a trend toward a decrease in 
lipids in MED13-knockdown larvae (Supplemental Figure 5). Simi-
larly, MED12 or MED13 knockdown had no effect on SREBP-1 in 
mammalian cells (data not shown). These results support a specific 
role of CDK8-CycC in lipid metabolism and are consistent with a 
previous report demonstrating functions for the CDK8-CycC com-
plex distinct from those of the MED12-MED13 complex in regulat-
ing developmental patterns in Drosophila (23). Our data also sup-
port a model whereby specific subunits of the Mediator complex are 
involved in only specific biological pathways, although the Mediator 
complex collectively may regulate most of the RNAPII-controlled 
gene expression. Alternatively, CDK8-CycC may function indepen-
dent of the Mediator complex. Mechanistically, CDK8-CycC inhib-
its lipid accumulation largely by repressing SREBP-mediated gene 
expression. Our biochemical analyses have revealed that SREBP-1c 
can be directly phosphorylated by CDK8 at a conserved T402 resi-
due (for human SREBP-1c) in vitro and in cultured mammalian 
cells. Furthermore, we observed that phosphorylation of SREBP-1 
at T402 promotes its degradation. Thus, this phosphorylation event 
provides a critical control mechanism to regulate the level of nucle-
ar SREBP-1c protein by increasing ubiquitination and subsequent 
rate of degradation without affecting the levels of the precursor 
SREBP-1c protein (Figure 3A, Figure 4A, and Figure 6A). These 
results suggest a simple explanation for the increased fat accumula-
tion on CDK8 or CycC mutants or in cells with reduced levels of 
CDK8 and CycC. That is, reduction of CDK8 or CycC will result in 
hypophosphorylation of SREBP-1, which increases the stability of 
the nuclear SREBP proteins, thereby allowing increased expression 
of SREBP target genes involved in de novo lipogenesis.
It has been known that phosphorylation of nuclear SREBP pro-
teins controls their stability (35, 55). GSK-3β, which functions 
downstream of insulin signaling, was previously reported to be 
involved in phosphorylation of SREBP proteins at several con-
served sites, including T426 of SREBP-1a (the site corresponding 
to T402 of SREBP-1c) (35, 55). In this study, we identified that 
CDK8 can directly phosphorylate the T402 site of SREBP-1c. It is 
not uncommon that the same threonine or serine residue of a pro-
tein can be phosphorylated by multiple kinases. The fact that the 
T402 site of SREBP-1c can be targeted by both GSK-3β and CDK8 
is consistent with the key role of phosphorylation on this site for 
the binding of the E3 ligase SCFFbw7b (35, 55).
The importance of these findings is underscored by the follow-
ing two points. First, the observed high rates of lipogenesis and 
enhanced SREBP-target gene expression in dyslipidemic states in 
CDK8 and CycC mutants cannot be solely accounted for by changes 
in SREBP-1c transcription or maturation. It will be important to 
determine whether the control over nuclear SREBP-1c protein levels 
through the CDK8-CycC complex can provide a mechanistic basis 
for the enigmatic enhancement of lipogenesis that occurs during 
insulin resistance and diabetes. Second, CDK8 has been recently 
identified as an oncoprotein in melanoma and colorectal cancers 
Figure 7
Regulation of CDK8 and CycC by feeding and insulin. (A) The indicated nuclear protein levels in livers of mice that were fasted for 12 hours (Fasted) 
or fasted for 12 hours followed by 5 hours re-feeding with normal mouse chow (Re-fed). (B and C) Effects of 200 nM insulin on the protein levels 
of CDK8 and CycC (B) and phosphorylation levels at TP motifs of immunoprecipitated SREBP-1c (C) in primary rat hepatocytes for 1 hour. (D) 
Effects of overexpressed CycC on insulin-mediated regulation of nuclear SREBP-1a in HEK293 cells. HA-tagged Gal4 DNA-binding domain–fused 
Myb-TAD served as the invariant control. (E) Effects of overexpressed CycC on insulin-induced activation of the FAS promoter in HEK293 cells by 
luciferase reporter assays. The firefly luciferase activity of each sample was normalized by the Renilla luciferase activity of cotransfected reporter 
under the control of a basal promoter (n = 3). (F) In Drosophila larvae, overexpression of CycC in fat body (FB-Gal4/UAS-CycC [FB>CycC+]) inhib-
its the re-feeding–induced increase in lipogenic gene expression. The third instar larvae were either fasted for 15 hours only or fasted for 15 hours 
followed by re-feeding for 5 hours. n = 3 with 10 larvae in each group; *P < 0.01 versus control (in the presence of insulin or re-fed).
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(56, 57). Aberrant lipid and carbohydrate metabolism is a univer-
sal feature of human cancer cells; however, the mechanisms linking 
such aberrant metabolism and tumorigenesis remain poorly under-
stood. Our results suggest that dysregulation of CDK8 may not only 
promote tumorigenesis, but also disrupt the cellular lipid homeo-
stasis by lifting its repressive effect on SREBP-dependent transcrip-
tion. It will be important to investigate in the future whether such 
a mechanism is functional in different types of human cancer cells.
Methods
Drosophila stocks and genetics. The w1118 and Oregon R Drosophila strains were 
used as controls. The null alleles of Cdk8 (w1118; +; FRT80B Cdk8K185/TM3 Sb) 
and CycC (w1118; +; FRT82B CycCY5/TM3 Sb) were provided by Henri-Marc 
Bourbon and Muriel Boube (Centre de Biologie du Développement, Uni-
versité Paul Sabatier, Toulouse, France), and we replaced the balancer chro-
mosome TM3 Sb with TM6B to facilitate the identification of homozygous 
mutant larvae. The fat body–specific Adh4-Gal4 and FB-Gal4 lines were 
obtained from Thomas Neufeld (Department of Genetics, University of 
Minnesota, Minneapolis, Minnesota, USA). The transgenic RNAi lines for 
Cdk8 and CycC were generated using the pVALIUM10 vector (58). Briefly, an 
845-bp fragment of the dCDK8 gene and an 838-bp fragment of the dCycC 
gene were chosen using the online SnapDragon program developed by the 
Norbert Perrimon laboratory (http://www.flyrnai.org/cgi-bin/RNAi_find_
primers.pl). The PCR primers were: dCDK8 forward, 5′-CACCGAGCG-
TACGAAAGTGGAGGA-3′; dCDK8 reverse, 5′-AGCGAGCAGGTGGAG-
TATGT-3′; dCycC forward, 5′-CACCGGCAATTTTTGGCAGAGTTC-3′; 
and dCycC reverse, 5′-TGGGCAATACCAGCTAATGA-3′. The PCR frag-
ments were cloned into entry vectors using a pENTR-D-TOPO cloning kit 
(Invitrogen), and the product was verified by diagnostic digestion. The frag-
ments were then recombined into the pVALIUM10 vector, and the final con-
structs were verified by DNA sequencing. To knock down dSREBP (HLH106), 
we generated a miRNA transgenic line using the pVALIUM20 vector, which 
was shown to efficiently knock down target genes in both soma and germ 
line (59). The primers were: dSREBP-1F, 5′-CTAGCAGTCCGGTTATGCT-
TAGATTGTAATAGTTATATTCAAGCATATTACAATCTAAGCATAAC-
CGGGCG-3′ and dSREBP-1R, 5′-AATTCGCCCGGTTATGCTTAGATTG-
TAATATGCTTGAATATAACTATTACAATCTAAGCATAACCGGACTG-3′. 
The final constructs were verified by DNA sequencing. UAS-CycC was 
constructed by inserting wild-type CycC cDNA (from Patrick O’Farrell, 
UCSF, San Francisco, California, USA) into the pTFHW vector (T. Murphy, 
Drosophila Genomic Resource Center, Bloomington, Indiana, USA), and the 
final construct was verified by sequencing. Transgenic flies were generated 
by injecting the vectors into early embryos (Genetic Services Inc). The trans-
genic RNAi lines were genetically combined with either Adh-Gal4 or FB-Gal4 
using standard Drosophila genetics.
Microarray analyses. Third instar larvae of Oregon R Drosophila (control), 
Cdk8-null (w1118; +; Cdk8K185), and CycC-null (w1118; +; CycCY5) were collected 
at the wandering stage. Total RNA was extracted from 10 larvae (triplicate 
for each genotype) with 1 ml of TRIzol Regent (Invitrogen) according to the 
manufacturer’s instructions. RNA quality was evaluated using the Agilent 
2100 Bioanalyzer (Agilent). RNA (1 μg) was used for Affymetrix One-Cycle 
Target Labeling as described by the manufacturer (Affymetrix). Each of 6 
Affymetrix Drosophila genome arrays was hybridized for 16–18 hours with 
biotin-labeled fragmented cRNA (10 μg) in 200 μl hybridization mixture 
according to the manufacturer’s protocol. Arrays were washed and stained 
using GeneChip Fluidic Station 450, and hybridization signals were ampli-
fied using antibody amplification with goat IgG (Sigma-Aldrich) and anti-
streptavidin biotinylated antibody. Chips were scanned on a Affymetrix 
GeneChip Scanner 3000 using Affymetrix Command Console Software. 
Raw data were normalized using Robust Multichip Average and normal-
ized to control samples with GeneSpring GX 11.0.2 software (Agilent). 
A volcano plot was used to identify differentially expressed genes using 
parametric testing assuming equal variances and no multiple testing cor-
rections. Pathway analysis of differentially expressed genes was performed 
employing Ingenuity software (Ingenuity Systems). The complete sets of 
microarray data have been deposited in the ArrayExpress database (http://
www.ebi.ac.uk/arrayexpress/; accession number E-MTAB-1066).
Oil red O staining and quantification. Drosophila larvae were partially dissected 
in 1× PBS and then fixed in 4% formalin in 1× PBS for 15 minutes at room 
temperature. After three quick rinses with distilled water, the female lar-
vae were stained with 5 ml of 0.036% oil red O (by mixing 6 ml of 0.1% oil 
red O in isopropanol with 10.5 ml distilled water, then filtering through a 
0.45-nm filter; Millipore) for 25 minutes at room temperature. After 2 quick 
rinses (1 minute for each) with 70% isopropanol and 1 quick rinse with dis-
tilled water, each larva was transferred into individual Eppendorf tubes and 
dried overnight. The oil red O from each larva was then extracted by adding 
0.3 ml isopropanol and rocking for 8 hours before measuring the O.D. at 
510 nm. The amount of oil red O staining was normalized to the control, 
and the results of at least 3 independent experiments were combined and 
presented. Slides of mouse livers were stained with oil red O similarly.
Antibodies. Anti-CDK8 (Abcam and Santa Cruz Biotechnology Inc.), 
anti–cyclin C (Invitrogen), anti–SREBP-1 (Santa Cruz Biotechnology Inc.), 
anti-FAS (Cell Signaling Technology), anti-Flag (Sigma-Aldrich), anti-HA 
(Covance), anti–p-TP (Cell Signaling Technology), anti–p-S (Invitrogen), 
anti–β-tubulin (Invitrogen), and anti-TBP (Fisher Scientific) antibodies 
were used in this study.
Tissue culture. HEK293, HepG2, and FAO cells were purchased from 
ATCC and cultured in Dulbecco’s modified Eagle’s medium (Gibco) sup-
plemented with 10% heat-inactivated fetal bovine serum (Hyclone), 2 mM 
l-glutamine (Gibco), 100 U/ml penicillin (Gibco), and 100 μg/ml strepto-
mycin (Gibco) at 37°C under humidified air containing 5% CO2. Primary 
rat hepatocytes were isolated by perfusion of rat livers by David Neufeld 
(Marion Bessin Liver Research Center, Albert Einstein College of Medi-
cine). For all perfusions, Chee medium (pH 7.2) was supplemented with 
10 mM HEPES. Washout medium was further supplemented with heparin 
(2.0 U/ml) and EGTA (0.5 mM), and digestion medium was supplemented 
with 500 mg/l collagenase. Viable primary rat hepatocytes were enriched 
by low-speed centrifugation (500 g) for 3 minutes. Typically, the yield of 
isolated hepatocytes was approximately 3 × 107 cells with a viability of great-
er than 80% as determined by trypan blue dye exclusion. The primary rat 
hepatocytes were further selected for experiments by seeding 1.5 × 106 cells 
on a 6-cm BD BioCoat dish (BD Biosciences) supplemented with low-glu-
cose DMEM (Gibco), 5% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 
and 2 mM l-glutamine. After approximately 4 hours of incubation, non-
adherent cells were washed twice with 1× PBS, and the resulting hepatocytes 
were cultured in the above DMEM medium for further treatment. For insu-
lin treatment, cells were fasted in serum-free medium for 4 hours.
Preparation of lentivirus. pGIPZ-shRNA plasmids were purchased from 
Thermo Scientific. Lentivirus was packaged by the TransLenti Viral GIPZ 
Packaging System (Thermo Scientific). The day before transfection of 
pGIPZ plasmids, HEK293T cells were plated at a density of 5.5 × 106 cells 
per 100-mm plate. For each plate, 9 μg plasmids and 28.5 μg viral pack-
aging mix were transfected into HEK293T cells by Arrest-In transfection 
reagent. Fiver hours after transfection, culture medium was replaced with 
regular DMEM. Transfection efficiency was then examined two days after 
transfection by the percentage of GFP-positive cells. Culture medium was 
collected at day 3 and centrifuged at 2,000 g for 20 minutes at 4°C. The 
virus-containing supernatant was kept at –80°C in aliquots.
Protein extraction and immunoblotting. For whole cell extracts, cells or 
homogenized mouse tissues were lysed in a buffer containing 50 mM Tris-
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Data analysis was performed by software provided with the StepOnePlus 
Real-Time PCR System. PCR primers are listed in Supplemental Table 2.
Mouse treatment. Male C57BL/6J mice purchased from The Jackson Labora-
tory were maintained under a 12-hour dark cycle with free access to water and 
standard mouse diet (10% calories from fat). For transient deletion of hepat-
ic CDK8, 8- to 10-week-old mice were injected with adenovirus (~1.5 × 109 
infectious particles per mouse) expressing nonspecific shRNA (control) 
or CDK8 shRNA (Welgen Inc.) through tail veins. For de novo lipogenesis 
experiments, 9 days after viral injection, food was removed in the morning 
and mice received an i.p. injection of deuterated water (2H2O) containing 
0.9% sodium chloride at a concentration of approximately 4% lean body 
mass. Mice were provided drinking water containing 4% 2H2O. Five hours 
later, mice were sacrificed, and pieces of liver tissues and plasma were sent 
to the Metabolic Center at Albert Einstein College of Medicine to determine 
the palmitate levels by gas chromatography and mass spectrometry.
Metabolites. Plasma triglyceride, glycerol, and non-esterfied fatty acid 
(NEFA) levels were measured using Infinity Triglycerides Reagent (Thermo 
Scientific), free glycerol reagent (Sigma-Aldrich), and HR Series NEFA-HR 
(Wako). Liver triglyceride levels were analyzed by an Adipogenesis Assay Kit 
(Biovision) and normalized by total protein levels.
Statistics. For quantitative measurement of mRNA, protein, triglycerides, 
oil red O staining, NEFA, glycerol, and insulin, the comparison of 2 differ-
ent groups was carried out using 2-tailed unpaired Student’s t test. Results 
are presented as mean ± SD. Differences was considered statistically sig-
nificant when P was less than 0.05.
Study approval. All experiments using mice and rats conformed to proto-
cols approved by the Animal Care and Use Committee of Albert Einstein 
College of Medicine.
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HCl (pH 8.0), 0.1 mM EDTA, 420 mM NaCl, 0.5% NP-40, 0.05% SDS, 10% 
glycerol, 1 mM dithiothreitol, 2.5 mM PMSF, 1 mM benzamidine, 1 mg/l 
aprotinin, and 0.1 mM of the calpain inhibitor ALLN (Santa Cruz Biotech-
nology Inc.). Supernatants were collected after centrifugation at 20,000 g 
for 20 minutes at 4°C. For nuclear extracts, cells or mouse tissues were 
first suspended in 5 volumes of buffer A (10 mM Tris-HCl pH 8.0, 1.5 mM 
MgCl2, 10 mM KCl, 1 mM dithiothreitol, 2.5 mM PMSF, 1 mM benzami-
dine, 1 mg/l aprotinin), homogenized in a glass homogenizer until approx-
imately 90% cells were broken, and centrifuged at 2,000 g for 5 minutes at 
4°C. The pellet was washed once with buffer A and resuspended in buffer 
C (20 mM Tris-HCl pH 8.0, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 
20% glycerol, 12% sucrose, 1 mM dithiothreitol, 2.5 mM PMSF, 1 mM ben-
zamidine, and 1 mg/l aprotinin). This suspension of nuclei was rotated at 
4°C for 40 minutes and centrifuged 20,000 g for 20 minutes at 4°C. Super-
natant was dialyzed against 500 volumes of buffer D (20 mM Tris-HCl 
pH 8.0, 100 mM KCl, 1.5 mM MgCl2, 0.1 mM EDTA, 20% glycerol, 1 mM 
dithiothreitol, 2.5 mM PMSF, and 1 mM benzamidine). After centrifuga-
tion at 20,000 g for 20 minutes at 4°C, the resulting supernatant was des-
ignated as nuclear extract. Protein concentrations were measured with a 
BCA kit (Pierce). A given amount of whole cell extract or nuclear extract 
was mixed with 5× SDS loading buffer (0.25 M Tris-HCl pH 6.8, 10% SDS, 
50% glycerol, 0.05% bromphenol blue, 500 mM dithiothreitol). After boil-
ing for 3 minutes, the proteins were resolved by NuPAGE 4%–12% Bis-Tris 
gel (Invitrogen) and transferred to nitrocellulose or PVDF membrane by 
iBlot Gel Transfer Kit (Invitrogen). After blocking in 5% nonfat milk in 1× 
TBST, the membrane was incubated with specific primary antibodies with 
appropriate dilution for 2 hours at room temperature and washed 3 times 
with 1× TBST (10 minutes each). Then, the membrane was incubated with 
the HRP-conjugated secondary antibodies (1:10,000 dilution) for 1 hour at 
room temperature. After washing 3 times with 1× TBST (10 minutes each), 
the HRP signals were visualized by the SuperSignal West Pico kit (Pierce) 
according to the manufacturer’s instructions.
In vitro kinase assay. Endogenous CDK8 proteins were immunoprecipitat-
ed from HEK293 cell nuclear extracts with anti-CDK8 antibody on protein 
A/G sepharose beads. Flag-tagged CDK8 proteins expressed in HEK293 
cells by transient transfection were immunoprecipitated using anti-Flag 
M2 affinity gel (Sigma-Aldrich). After incubation for 2 hours at 4°C, pro-
tein A/G sepharose or anti-Flag beads were washed 3 times with IP buf-
fer and mixed with GST proteins. The mixture was washed once with the 
kinase buffer (50 mM Tris-HCl pH 7.4, 50 mM NaCl, 10 mM MgCl2, 1 mM 
MnCl2 and 10% glycerol) and incubated in 50 μl of kinase buffer contain-
ing 50 mM ATP for 1 hour at 30°C. The reaction was terminated by boiling 
in 5× SDS loading buffer. The phosphorylation signals were detected using 
specific anti–p-TP and anti–p-S antibodies.
RNA preparation and quantitative PCR analysis. Total RNA was isolated 
from cells and mouse livers using the TRIzol reagent (Invitrogen) accord-
ing to the manufacturer’s protocol. RNA concentration was measured by 
a NanoDrop spectrophotometer (Thermo). After removing genomic DNA 
with RQ1 RNase-free DNase I (Promega), cDNA was synthesized by a 
First-Strand cDNA Synthesis Kit (GE Healthcare). Synthesized cDNA was 
diluted for real-time PCR. Each real-time PCR reaction mixture contained 
10 μl FastStart universal SYBR Green Master mix (Roche), 1 μl primer 
(250 nM each), and 9 μl diluted cDNA. Real-time PCR was performed 
using the StepOnePlus Real-Time PCR System (Applied Biosystems). 
The cycling parameters consisted of 95°C incubation for 10 minutes for 
enzyme activation and DNA denaturation, followed by 40 PCR amplifica-
tion cycles consisting of 95°C for 15 seconds and 60°C for 1 minute. The 
thermocycling program was followed by a melting program of 95°C for 15 
seconds (denaturation), 60°C for 1 minute (annealing), and then 60–95°C 
at a transition rate of 0.3°C/s with continual monitoring of fluorescence. 
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